INSY Insys Therapeutics Inc.

4.21
-0.09  -2%
Previous Close 4.3
Open 4.3
Price To Book -7.26
Market Cap 313342975
Shares 74,428,260
Volume 586,792
Short Ratio
Av. Daily Volume 928,594

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 data likely due 2Q 2019
Cannabidiol
Refractory childhood absence epilepsy
Approved January 5, 2012.
SUBSYS
Cancer pain
Phase 2 initiated August 2016
Pharmaceutical Cannabidiol (CBD)
Cocaine dependence
Announced approval July 5, 2016.
Dronabinol Oral Solution
AIDS-related anorexia
Phase 3 initiation announced March 2, 2018. Noted December 18, 2018 that enrolment has occurred at slower pace than expected.
Pharmaceutical Cannabidiol (CBD)
Infantile spasms (IS)
CRL issued July 27, 2018.
Buprenorphine
Moderate to severe postoperative pain after bunionectomy
NDA filing likely due 2Q 2019 following data from nonclinical juvenile toxicity trial.
Naloxone nasal spray
Opioid overdose
Phase 2 data due 2H 2019.
Cannabidiol
Prader-Willi syndrome